Immunogenicity and Safety of a Purified Vero Rabies Vaccine

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-17

Study Completion Date

2018-01-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This multicenter, observer-blind, controlled, randomized, Phase II study was designed to evaluate different formulations of the Purified Vero Rabies Cell vaccine VRVg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

NCT01877395

Rabies

COMPLETED PHASE2

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

NCT03965962

Rabies (Healthy Volunteers)

COMPLETED PHASE3

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

NCT01784874

Rabies

COMPLETED PHASE2

Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen

NCT01930357

Rabies

COMPLETED PHASE2

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults

NCT04127786

Rabies Healthy Volunteers

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study assessed different formulations of the modified formulation of VRVg (VRVg 2- formulations 1 \[low\], 2 \[medium\] and 3 \[high\]) tested in parallel to the initial VRVg formulation (VRVg-1) and Imovax Rabies. Immune responses were assessed at Day 14, Day 28, Day 42, and at Month 7. Safety events were also reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rabies Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: VRVg-2 Formulation 1

VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.

Group Type EXPERIMENTAL

VRVg 2

Intervention Type BIOLOGICAL

Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free

Human Rabies Immunoglobulins (HRIG)

Intervention Type BIOLOGICAL

Commercialized formulation of HRIG

Group 2: VRVg-2 Formulation 2

VRVg-2 formulation 2, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.

Group Type EXPERIMENTAL

VRVg 2

Intervention Type BIOLOGICAL

Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free

Human Rabies Immunoglobulins (HRIG)

Intervention Type BIOLOGICAL

Commercialized formulation of HRIG

Group 3: VRVg-2 Formulation 3

VRVg-2 formulation 3, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.

Group Type EXPERIMENTAL

VRVg 2

Intervention Type BIOLOGICAL

Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free

Human Rabies Immunoglobulins (HRIG)

Intervention Type BIOLOGICAL

Commercialized formulation of HRIG

Group 4: VRVg-1

VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.

Group Type EXPERIMENTAL

VRVg 1

Intervention Type BIOLOGICAL

Initial formulation of Purified Vero Rabies Vaccine Serum Free

Human Rabies Immunoglobulins (HRIG)

Intervention Type BIOLOGICAL

Commercialized formulation of HRIG

Group 5: Imovax Rabies

Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.

Group Type ACTIVE_COMPARATOR

Imovax Rabies

Intervention Type BIOLOGICAL

Purified inactivated rabies vaccine prepared on human diploid cell cultures

Human Rabies Immunoglobulins (HRIG)

Intervention Type BIOLOGICAL

Commercialized formulation of HRIG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VRVg 2

Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free

Intervention Type BIOLOGICAL

VRVg 1

Initial formulation of Purified Vero Rabies Vaccine Serum Free

Intervention Type BIOLOGICAL

Imovax Rabies

Purified inactivated rabies vaccine prepared on human diploid cell cultures

Intervention Type BIOLOGICAL

VRVg 2

Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free

Intervention Type BIOLOGICAL

VRVg 2

Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free

Intervention Type BIOLOGICAL

Human Rabies Immunoglobulins (HRIG)

Commercialized formulation of HRIG

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

An individual must fulfill all of the following criteria in order to be eligible for trial enrollment:

1. Aged 18 to less than 65 years on the day of inclusion.
2. Informed consent form had been signed and dated.
3. Able to attend all scheduled visits and to complied with all trial procedures.
4. Body Mass Index (BMI): 18.5 kilograms per meter square (Kg/m\^2) less than or equal to (\<=) BMI \<= 30 Kg/m\^2.

Exclusion Criteria

An individual fulfilling any of the following criteria was to be excluded from trial enrollment:

1. Participant was pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile.
2. Participation at the time of study enrollment or, planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
3. Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination or planned receipt of any vaccine prior to Visit 6.
4. Previous vaccination against rabies (in pre- or post-exposure regimen) with either the trial vaccine or another vaccine.
5. Receipt of immune globulins, blood or blood-derived products in the past 3 months.
6. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
7. At high risk for rabies infection during the trial (e.g., veterinarians and staff, animal handlers, rabies researchers, or any others whose activities may bring them into frequent contact with rabies virus or animals who had the rabies virus).
8. Known systemic hypersensitivity to any of the vaccine or human rabies immunoglobulins (HRIG) components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
9. Self-reported thrombocytopenia, contraindicating IM vaccination.
10. Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
11. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
12. Current alcohol abuse or drug addiction.
13. Chronic illness that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion (e.g., cardiac disorders, renal disorders, auto immune disorders, diabetes, psychiatric disorders or chronic infection).
14. Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature greater than or equal to \[\>=\] 100.4 Fahrenheit \>=38.0 Celsius). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.
15. Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
16. History of Guillain-Barré syndrome.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes